title: Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice.
abstract: OBJECTIVE
  To collect data on the efficacy and safety of omalizumab in 110 patients from 9 Spanish hospitals suffering from chronic spontaneous urticaria (CSU) refractory to conventional treatment.
  
  
  METHODS
  A retrospective, descriptive analysis was performed, showing the data of 110 patients suffering from refractory CSU who received omalizumab as an off-label treatment in 9 Spanish hospitals from October 2009 to September 2012.
  
  
  RESULTS
  Ninety (81.8%) patients exhibited a complete or significant response, 12 (10.9%) had partial response, and 8 (7.2%) showed no response. Sixty-six (60%) patients were able to stop all concomitant medications, remaining asymptomatic treated with omalizumab alone. No serious adverse events were reported.
  
  
  CONCLUSIONS
  Omalizumab shows excellent efficacy and safety profile in a large series of CSU patients in real-life practice. This drug will contribute to settle the debt with CSU patients contributing to restore their quality of life.
authors.affiliation: Allergy Section, Medicine Department, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron, 119-129, 08035, Barcelona, Spain. mlabrador@vhebron.net
authors.forename: Moises
authors.initials: M
authors.lastname: Labrador-Horrillo
authors.forename: Antonio
authors.initials: A
authors.lastname: Valero
authors.forename: Manuel
authors.initials: M
authors.lastname: Velasco
authors.forename: Ignacio
authors.initials: I
authors.lastname: Jáuregui
authors.forename: Joaquin
authors.initials: J
authors.lastname: Sastre
authors.forename: Joan
authors.initials: J
authors.lastname: Bartra
authors.forename: Juan Francisco
authors.initials: JF
authors.lastname: Silvestre
authors.forename: Javier
authors.initials: J
authors.lastname: Ortiz de Frutos
authors.forename: Ana
authors.initials: A
authors.lastname: Gimenez-Arnau
authors.forename: Marta
authors.initials: M
authors.lastname: Ferrer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D013030:Spain; D014581:Urticaria / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab